摘要
目的:探讨多西他赛、奥沙利铂联合替吉奥在进展期胃癌新辅助化疗中的临床疗效。方法:选取2011年8月—2013年6月复旦大学附属肿瘤医院闵行分院收治的进展期胃癌患者128例,以随机数字表法分为观察组和对照组各64例。观察组患者给予多西他赛、奥沙利铂联合替吉奥治疗,对照组患者给予多西他赛、奥沙利铂联合氟尿嘧啶治疗,比较2组患者化疗期间的肿瘤浸润情况、不良反应的发生率、术后完全(RO)切除率、1年及2年生存率。结果:观察组患者肿瘤浸润至浆膜层及肌层的比例明显低于治疗前及对照组患者治疗后,差异均有统计学意义(P<0.05);观察组患者不良反应发生率明显低于对照组,RO切除率、1年及2年生存率均显著高于对照组,差异均有统计学意义(P<0.05)。结论:多西他赛、奥沙利铂联合替吉奥治疗进展期胃癌,可显著缩小肿瘤病灶,减少不良反应,延长患者生存时间。
OBJECTIVE:To probe into the clinical efficacy of docetaxel, oxaliplatin combined with gimeracil and oteracil porassium capsules in neoadjutant chemotherapy for advanced gastric cancer.METHODS:128 patients with adjutant chemotherapy for advanced gastric cancer admitted into Tumor Hospital of Minhang Branch Affiliated to Fudan University from Aug.2011 to Jun.2013 were selected to be divided into observation group and control group via the random number table, with 64 cases in each.The observation group were treated with docetaxel, oxaliplatin combined with gimeracil and oteracil porassium capsules, while the control group received docetaxel, oxaliplatin combined with 5-fluorouracil chemotherapy.The tumor infiltration, incidence of adverse drug reactions in two groups were compared;the RO resection rate, 1-year and 2-year survival rate of two groups were statistically collected.RESULTS: After intervention, the ratio of tumor infiltration to serosa and muscle in observation group was significantly lower than that of before intervention and after intervention in control group, with statistically significant difference ( P 〈0.05 ) .The incidence of adverse drug reactions of observation group was significantly lower than that of control group, the RO resection rate, 1-year and 2-year survival rate of observation group were significantly higher than that of control group, with statistically significant difference(P〈0.05).CONCLUSIONS: Docetaxel, oxaliplatin combined with gimeracil and oteracil porassium capsules in treatment of advanced gastric cancer can significantly shorten tumor lesions, reduce adverse drug reactions and prolong the survival time of patients.
出处
《中国医院用药评价与分析》
2016年第8期1027-1029,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
上海市闵行区卫计委科研课题项目(No.2013MW29)
关键词
替吉奥
DOS方案
进展期胃癌
新辅助化疗
Gimeracil and oteracil porassium capsules
DOS program
Advanced gastric cancer
Neoadjuvant chemotherapy